Related references
Note: Only part of the references are listed.Sensitivity of HIV type 1 primary isolates to human Anti-CD40 antibody-mediated suppression is related to coreceptor use
Sisay A. Abayneh et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1
J. Garcia-Perez et al.
HIV MEDICINE (2008)
Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays
Leo Heyndrickx et al.
JOURNAL OF VIROLOGICAL METHODS (2008)
Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models
Bruce K. Brown et al.
VIROLOGY (2008)
Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides
Katherine E. Gantlett et al.
ANTIVIRAL RESEARCH (2007)
Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies
Esther D. Quakkelaar et al.
JOURNAL OF VIROLOGY (2007)
A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1
J. Garcia-Perez et al.
JOURNAL OF MEDICAL VIROLOGY (2007)
Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration
Vidita Choudhry et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells
Vincent Holl et al.
JOURNAL OF VIROLOGY (2006)
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains
P Lusso et al.
JOURNAL OF VIROLOGY (2005)
Identifying epitopes of HIV-1 that induce protective antibodies
S Zolla-Pazner
NATURE REVIEWS IMMUNOLOGY (2004)
The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope
MK Gorny et al.
JOURNAL OF VIROLOGY (2004)
Involvement of FcγR I (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages
V Holl et al.
JOURNAL OF IMMUNOLOGY (2004)
Epitopes corresponding to the envelope genetic subtype are present on the surface of free Virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases
D Davis et al.
JOURNAL OF MEDICAL VIROLOGY (2003)
HIV vaccines: A global perspective
J Esparza et al.
CURRENT MOLECULAR MEDICINE (2003)
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
DD Richman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Therapeutic dendritic-cell vaccine for simian AIDS
W Lu et al.
NATURE MEDICINE (2003)
A new cell line-based neutralization assay for primary HIV type 1 isolates
Y Shi et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2002)
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120
CN Scanlan et al.
JOURNAL OF VIROLOGY (2002)
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells
JR Mascola et al.
JOURNAL OF VIROLOGY (2002)
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
MB Zwick et al.
JOURNAL OF VIROLOGY (2001)
Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system
G Jármy et al.
JOURNAL OF MEDICAL VIROLOGY (2001)
HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies
VR Polonis et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2001)
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection
MJ McElrath et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2000)
Share Paper
